Status:
COMPLETED
Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom
Lead Sponsor:
Pfizer
Conditions:
Candidiasis
Eligibility:
All Genders
18-90 years
Brief Summary
The purpose of this study is to describe the real world effectiveness of anidulafungin in clinical practice in a large Liver Unit in the United Kingdom.
Detailed Description
All subjects that have been treated with Anidulafungin according to its licence during the period of July 2009 and September 2010 will be included.
Eligibility Criteria
Inclusion
- Subjects who have been prescribed anidulafungin between 1st July 2009 and 30th September 2010.
- Patients admitted to specialist liver unit wards and the Liver Intensive Therapy Unit during this period
Exclusion
- Patients who participated in any interventional clinical trial during this episode of sepsis.
- Patients who received anidulafungin for infection prophylaxis
Key Trial Info
Start Date :
February 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01202253
Start Date
February 1 2011
End Date
May 1 2011
Last Update
April 16 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
London, United Kingdom, SE5 9RS